Smith & Nephew (LSE:SN.) has priced $700 million of 5.750% notes due 2036, generating net proceeds of $690.9 million after underwriting discounts.
The London and New York-listed medical technology group, which makes products for orthopaedics, sports medicine and wound care, will use the proceeds to fund a tender offer for its outstanding 2.032% senior notes due 2030.
Remaining funds after fees and expenses will go toward general corporate purposes.
The refinancing swaps 2030 debt carrying a 2.032% coupon for longer-dated 2036 notes at 5.750%, extending the maturity profile at a materially higher rate, reflecting the shift in borrowing costs since the earlier notes were issued.
The offering is scheduled to close on 11 September, subject to customary conditions.
News Intelligence what this means for the company
Smith & Nephew has priced $700 million of 2036 notes at 5.750% to fund a tender offer for its 2030 notes carrying a 2.032% coupon, extending debt maturity by six years at a materially higher borrowing cost. This refinancing, which follows the company's launch of a $250 million tender offer on 8 September, locks in higher rates reflecting the shift in market conditions since the earlier notes were issued, but provides runway to manage near-term debt maturities.
The refinancing extends Smith & Nephew's debt maturity profile and reduces near-term refinancing risk, but at a cost: the 5.750% coupon is nearly 3.7 percentage points higher than the 2.032% it replaces, increasing annual interest expense on the refinanced portion. This comes as Deutsche Bank maintained a Hold rating citing slower orthopaedics recovery, suggesting the company faces operational headwinds alongside higher financing costs.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
